ZZM-1220 is a histone lysine metltransferase G9a/GLP covalent inhibitor with IC50s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase.
References:
[1]. Qiangsheng Zhang, et al. Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem. 2023 Sep 28:261:115841.
















